CRISPR Therapeutics AG
CRSP
View Detailed Chart
51.395USD
-1.955-3.66%
Market hours （ET）Quotes delayed by 15 min
4.82BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.66%
5 Days
-15.48%
1 Month
-4.77%
6 Months
-12.92%
Year to Date
-1.99%
1 Year
+24.71%
View Detailed Chart
TradingKey Stock Score of CRISPR Therapeutics AG
Currency: USD Updated: 2026-01-29Key Insights
CRISPR Therapeutics AG's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 81.52.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CRISPR Therapeutics AG's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
CRISPR Therapeutics AG Highlights
StrengthsRisks
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 3014.69% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.31M.
Fairly Valued
The company’s latest PE is -9.63, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 79.52M shares, increasing 0.09% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 10.68K shares of this stock.
Analyst Rating
Based on
29
analysts
Buy
Current Rating
81.524
Target Price
+50.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CRISPR Therapeutics AG News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CRISPR Therapeutics AG Info
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Ticker SymbolCRSP
CompanyCRISPR Therapeutics AG
CEOKulkarni (Samarth)
Websitehttps://crisprtx.com/
Related Instruments
+0.11%
-0.52%
+0.24%
+0.41%
+0.46%
+0.42%
-1.01%
-0.62%
+0.59%
-0.48%
-1.06%
+1.74%
+0.52%
+1.19%
+0.02%
+1.41%
+0.37%
0.00%
-0.50%
-0.58%Popular Symbols
256.450
-1.830 (-0.71%)
191.580
-0.930 (-0.48%)
83300.440
-878.510 (-1.04%)
266.710
-11.700 (-4.20%)
2735.300
-68.050 (-2.43%)
425.640
+9.080 (+2.18%)
5034.860
-358.740 (-6.65%)
65.268
+0.030 (+0.05%)
1.189
-0.007 (-0.60%)
154.652
+1.540 (+1.01%)
